|Traded as||NYSE: PRGO
S&P 500 Component
|John Hendrickson, Chairman, President and CEO|
|Products||OTC, RX, API, Medical Diagnostic, pharmaceuticals|
|Revenue||$3,540 million (2013)|
|$ 530 million (2013)|
Number of employees
|10,220 (May 2015)|
Perrigo Company plc is an American international manufacturer of private label over-the-counter pharmaceuticals. The company’s shares are traded on the NYSE and the Tel Aviv Stock Exchange; as a result of the merger with Agis Industries the company is a constituent of the TA-25 Index. Perrigo is the only non-Israeli company on the TA-25.
Perrigo Company plc, through its wholly owned subsidiaries, engages in the manufacture and sale of consumer healthcare products, generic prescription drugs, active pharmaceutical ingredients (API), and consumer products primarily in the United States, Australia, Israel, Europe, India and Mexico.
In March 2005 the firm acquired Agis Industries Ltd. (TASE:AGIS), an Israel-based generic pharmaceuticals company in an $850 million transaction. Agis was founded in 1983 by Mori Arkin who developed his father's small drug import business into a multinational generic pharmaceutical company. As a result of the acquisition Arkin owns 9% of Perrigo, and was appointed as Vice Chairman of the company.
In April 2015, Perrigo received a buy-out offer from Mylan for a fee of $29 billion. In May 2016 Perrigo investors sued the company over misleading statements made during Mylans hostile takeover attempt. Those false statements are said to have persuaded shareholders to vote against the deal.
On 9 January 2008, the firm acquired Galpharm Healthcare, Ltd., a supplier of over-the-counter store brand pharmaceuticals in the United Kingdom. On 16 September 2008, the firm acquired J.B. Laboratories. On 6 October 2008, it acquired Laboratorios Diba S.A., enabling the company to market its products in Mexico. On 13 November 2008, it acquired Unico Holdings, a manufacturer of store brand pediatric electrolytes, enemas and feminine hygiene products for retail consumers in the U.S.
On 1 March 2010, the firm acquired Orion Laboratories Pty, Ltd. a supplier of over-the-counter (OTC) store brand pharmaceutical products in Australia and New Zealand. On 23 March 2010, it acquired PBM Holdings, Inc.,a producer of over-the-counter store brand infant formula and baby foods in the United States, Canada, Mexico and China.
On 20 January 2011, the firm announced that it would acquire Paddock Laboratories Inc., with the deal expected to close in fiscal 2012.
In September 2012, Perrigo announced its intention to enter the animal wellness category by acquiring the assets of Sergeant's Pet Care Products, Inc., a privately held manufacturer of over-the-counter companion animal healthcare products.
On 11 February 2013, Perrigo announced the completion of the acquisition of Rosemont Pharmaceuticals Ltd., a specialty and generic prescription pharmaceutical company focused on the manufacturing and marketing of oral liquid formulations. On 29 July 2013, the firm announced that it would acquire Élan, a major drugs firm based in Dublin. The Élan merger allowed Perrigo to reincorporate as an Irish company using Élan's headquarters (although the executive offices will remain in Allegan), lowering its effective tax rate significantly.
In November 2014, Perrigo announced it had agreed to buy Belgian health-products provider Omega Pharma approximately $4.5 billion(€3.6 billion). The transaction was completed in March 2015.
The following is an illustration of the company's major mergers and acquisitions and historical predecessors:
The company operates in three segments; Consumer Healthcare, Rx Pharmaceuticals, and Active Pharmaceutical Ingredients. The Consumer Healthcare segment produces over-the-counter pharmaceutical and nutritional products in the United States, the United Kingdom, and Mexico. This segment offers analgesic, cough/cold/allergy/sinus, gastrointestinal, smoking cessation, first aid, antacids, hemorrhoidal remedies, motion sickness, sleep aid products, feminine hygiene products, vitamin, and nutritional supplement products.
The Rx Pharmaceuticals segment produces generic prescription drugs in the United States. This segment provides creams, ointments, lotions, gels, and solutions, as well as nasal sprays, foams, and transdermal devices.
The Active Pharmaceutical Ingredients segment produces pharmaceutical ingredients in Israel with sales to customers worldwide. The company also offers cosmetics, toiletries, detergents, manufactured and imported pharmaceutical products, and medical diagnostic products. The company’s customers include national and regional retail drug, supermarket, wholesalers, and mass merchandise chains.
John T. Hendrickson is the Chief Executive Officer.
- 101 Best and Brightest Companies to Work For of West Michigan awarded Perrigo overall "Best of the Best" for 2009.
- In 2010 Perrigo was named one of the top 100 Fastest-Growing Companies by Fortune Magazine.
- Jones, Al (16 August 2011). "Perrigo Co. reports strong gains in sales and earnings for fourth quarter and full year". Mlive.com. Allegan. Kalamazoo Gazette. Retrieved 20 August 2011.
Sales for the full year were $2.75 billion, up about 21.5 percent from $2.26 billion in fiscal 2010.
- Wilton, Bill (2008-10-16). "Perrigo Company". Zacks Investment Research. Company Description. Archived from the original on 2008-10-22.
- "Perrigo Company - Company History", Funding Universe, retrieved 2009-10-31
- "Perrigo Company to Acquire Agis Industries, Creating A Leading Diversified Healthcare Company" (PDF) (Press release). Company press release. Retrieved October 31, 2009.
- "Generic drugmaker Mylan offers $29 billion for Perrigo" (Press release). Reuters. 8 April 2015.
- "Investor Sues Perrigo Over Disclosures in Mylan Hostile Bid".
- "Lawsuit filed against former Mylan acquisition target Perrigo - Pittsburgh Business Times".
- "Perrigo Investor Slams Co. Over Mylan's Failed Takeover - Law360".
- "Official Perrigo Company Press Release" (PDF). Retrieved 2012-03-13.
- "Official Perrigo Company Press Release" (PDF). Retrieved 2012-03-13.
- "Perrigo Closes Acquisition Of Sergeant's Pet Care Products". Perrigo Company.
- "Perrigo Company Acquires U.K.-based Rosemont Pharmaceuticals Ltd. For Approximately £180 Million Or $283 Million".
- Reuters (29 July 2013). "US-Generikakonzern: Perrigo kauft irische Pharmafirma Elan". handelsblatt.com.
- "This page has been removed - News - The Guardian". the Guardian.
- Pogatchnik, Shawn (29 July 2013). "Perrigo to buy Elan, reincorporate in Ireland". Boston Globe. Retrieved 20 January 2015.
- Risser, David (6 November 2014). "Perrigo to Buy Omega Pharma of Belgium for $4.5 Billion". Bloomberg.
- "Belgian newspaper De standaard reports Perrigo to Buy Omega Pharma for €3.6 Billion". De Standaard. 6 November 2014.
- "Perrigo Company plc Completes Acquisition Of Omega Pharma Invest N.V., Creating A Top Five Global OTC Company". PR Newswire Association LLC. PR Newswire. 30 March 2015. Retrieved 1 July 2015.
- "Struggling Perrigo inks deal agreement for GA-based distributor - FiercePharma".
- "Perrigo InvestorRoom - Members of Perrigo's Board of Directors". perrigo.com.
- "West Michigan 2009 Winners". 101 Best and Brightest Companies To Work For. West Michigan Region. Archived from the original on 2014-02-22.
- "100 Fastest-Growing Companies 2010 - from FORTUNE". Money.cnn.com. 2010-09-06. Retrieved 2012-03-13.